Anti-ZMPSTE24 antibody - Carboxyterminal end (ab53533)


  • Product name
    Anti-ZMPSTE24 antibody - Carboxyterminal end
    See all ZMPSTE24 primary antibodies
  • Description
    Goat polyclonal to ZMPSTE24 - Carboxyterminal end
  • Tested applications
    Suitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Chimpanzee, Rhesus monkey, Orangutan
  • Immunogen

    Synthetic peptide:


    , corresponding to C terminal amino acids 464-475 of Human ZMPSTE24

  • Positive control
    • Human Skin lysate



Our Abpromise guarantee covers the use of ab53533 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    ELISA: Peptide ELISA: Antibody detection limit dilution 1/128000.
    WB: Use at a concentration of 0.5 - 1.5 µg/ml. Detects a band of approximately 55 kDa (predicted molecular weight: 55 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Proteolytically removes the C-terminal three residues of farnesylated proteins. Acts on lamin A/C.
    • Tissue specificity
      Widely expressed. High levels in kidney, prostate, testis and ovary.
    • Involvement in disease
      Defects in ZMPSTE24 are the cause of mandibuloacral dysplasia with type B lipodystrophy (MADB) [MIM:608612]. Mandibuloacral dysplasia (MAD) is a rare autosomal recessive disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, joint contractures, and types A or B patterns of lipodystrophy. Type B lipodystrophy observed in MADB, is characterized by generalized fat loss.
      Defects in ZMPSTE24 are a cause of lethal tight skin contracture syndrome (LTSCS) [MIM:275210]; also called restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.
    • Sequence similarities
      Belongs to the peptidase M48A family.
    • Cellular localization
      Endoplasmic reticulum membrane. Golgi apparatus membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • CAAX prenyl protease 1 homolog antibody
      • FACE-1 antibody
      • FACE1 antibody
      • FACE1_HUMAN antibody
      • Farnesylated proteins converting enzyme 1 antibody
      • Farnesylated proteins-converting enzyme 1 antibody
      • Prenyl protein specific endoprotease 1 antibody
      • Prenyl protein-specific endoprotease 1 antibody
      • STE24 antibody
      • Zinc metalloproteinase Ste24 homolog antibody
      • zmpste24 antibody
      see all

    Anti-ZMPSTE24 antibody - Carboxyterminal end images

    • ab53533 antibody (0.5 µg/ml) staining of ZMPSTE24 in Human Skin lysate (35µg protein in RIPA buffer)

      Predicted band size : 55 kDa
      Observed band size : 55 kDa

    References for Anti-ZMPSTE24 antibody - Carboxyterminal end (ab53533)

    ab53533 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab53533.
    Please use the links above to contact us or submit feedback about this product.


    Sign up